Crystalline form of fluvatinib methanesulfonate and method for its manufacture
DE602021053770T2Active Publication Date: 2026-05-06CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO LTD +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO LTD
- Filing Date
- 2021-03-16
- Publication Date
- 2026-05-06
AI Technical Summary
Technical Problem
The polymorphic properties of fluvatinib methanesulfonate salts, such as different stability and solubility, complicate drug quality control, necessitating the development of a crystalline form with improved stability and druggability.
Method used
The development of crystalline forms I and III of fluvatinib mesylate, characterized by specific X-ray powder diffraction peaks, which exhibit enhanced stability and solubility, are prepared through controlled solvent stirring and drying processes.
Benefits of technology
The crystalline forms I and III maintain stability under harsh conditions and exhibit better solubility, making them suitable for pharmaceutical formulations and effective as angiogenesis inhibitors for treating various cancers.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.